ReviewCurrent treatment options in oncology2025
Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
opinion statementExtensive-stage small cell lung cancer (ES-SCLC) remains a challenging disease with a poor prognosis, despite recent advances in immunotherapy. The integration of thoracic radiotherapy (TRT) with chemoimmunotherapy has emerged as a promising strategy to improve treatment outcomes. However, the optimal role and timing of TRT in the first-line treatment of ES-SCLC in the immunotherapy era are still under investigation. Traditional approaches to TRT, based on high-dose regimens, have shown limited efficacy in overcoming the immunosuppressive tumor microenvironment (TME) characteristic of SCLC. The advent of low-dose radiotherapy (LDRT) offers a novel perspective by modulating the TME to enhance antitumor immunity. This review aims to re-evaluate the role of TRT, particularly LDRT, in the context of evolving immunotherapy strategies for ES-SCLC. By examining recent clinical trials and preclinical studies, we discuss the potential mechanisms through which LDRT can reshape the TME, promote immune activation, and improve the efficacy of immunotherapy. Additionally, we highlight the ongoing clinical trials that are essential for validating these approaches and determining the optimal treatment paradigms.
Indexed as
Identifiers
40742638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.